Table 2.
Logistic Regression Results Modeling Nesiritide Use, Heart Failure Population for January 2004–December 2005 (n = 295 901)
| January 2004-April 2005 (n = 206 458) |
May 2005-December 2005 (n = 89 443) |
||||||
|---|---|---|---|---|---|---|---|
| Variables | OR (95% CI) | P Value | Patients Taking Nesiritide, % | OR (95% CI) | P Value | Patients Taking Nesiritide, % | OR Change, P Value |
| Age, y | |||||||
| 19-64 | 1.00 | 15.0 | 1.00 | 8.2 | |||
| 65-74 | 1.17 (1.13-1.22) | <.001 | 16.5 | 1.07 (0.99-1.15) | .08 | 8.9 | .03 |
| 75-84 | 1.14 (1.10-1.19) | <.001 | 15.2 | 1.04 (0.97-1.12) | .30 | 8.1 | .02 |
| ≥85 | 0.96 (0.92-1.01) | .09 | 11.5 | 0.83 (0.76-0.91) | <.001 | 5.7 | .003 |
| Race | |||||||
| Black | 0.90 (0.87-0.93) | <.001 | 13.9 | 0.93 (0.87-0.99) | .02 | 7.9 | .35 |
| Other | 1.00 | 14.9 | 1.00 | 7.8 | |||
| Sex | |||||||
| Men | 1.24 (1.20-1.27) | <.001 | 16.9 | 1.16 (1.10-1.22) | <.001 | 8.9 | .02 |
| Women | 1.00 | 12.8 | 1.00 | 6.8 | |||
| Concurrent therapy* | |||||||
| ACE inhibitor | 0.93 (0.90-0.95) | <.001 | 14.9 | 0.88 (0.83-0.93) | <.001 | 7.9 | .08 |
| No ACE inhibitor | 1.00 | 14.5 | 1.00 | 7.7 | |||
| ARB | 1.07 (1.03-1.10) | <.001 | 15.9 | 0.99 (0.92-1.06) | .74 | 8.3 | .055 |
| No ARB | 1.00 | 14.5 | 1.00 | 7.8 | |||
| β-Blocker | 1.62 (1.57-1.66) | <.001 | 17.4 | 1.60 (1.51-1.70) | <.001 | 9.1 | .79 |
| No β-blocker | 1.00 | 10.4 | 1.00 | 5.2 | |||
| Digoxin | 1.26 (1.23-1.30) | <.001 | 18.2 | 1.27 (1.20-1.34) | <.001 | 9.9 | .87 |
| No digoxin | 1.00 | 13.1 | 1.00 | 7.0 | |||
| Aldosterone antagonist | 1.66 (1.61-1.71) | <.001 | 22.0 | 1.63 (1.54-1.72) | <.001 | 12.1 | .56 |
| No aldosterone antagonist | 1.00 | 12.6 | 1.00 | 6.6 | |||
| Hospital type | |||||||
| Urban | 1.01 (0.97-1.05) | .56 | 14.7 | 0.83 (0.77-0.89) | <.001 | 7.7 | <.001 |
| Rural | 1.00 | 14.8 | 1.00 | 9.0 | |||
| Nonteaching | 0.99 (0.96-1.02) | .55 | 14.4 | 0.78 (0.74-0.83) | <.001 | 7.6 | <.001 |
| Teaching | 1.00 | 15.2 | 1.00 | 8.3 | |||
| Hospital bed count | |||||||
| 0-100 | 0.69 (0.64-0.74) | <.001 | 9.4 | 0.77 (0.67-0.88) | <.001 | 5.6 | .17 |
| 101-400 | 1.00 | 15.1 | 1.00 | 8.5 | |||
| 401-600 | 0.95 (0.92-0.98) | <.001 | 14.6 | 0.76 (0.71-0.81) | <.001 | 7.0 | <.001 |
| >601 | 0.83 (0.81-0.86) | <.001 | 15.0 | 0.69 (0.64-0.74) | <.001 | 7.8 | <.001 |
| Physician | |||||||
| Cardiologist | 1.93 (1.88-1.99) | <.001 | 23.0 | 1.80 (1.71-1.90) | <.001 | 12.2 | .02 |
| Other | 1.00 | 12.2 | 1.00 | 6.4 | |||
| Region | |||||||
| Midwest | 1.67 (1.59-1.75) | <.001 | 17.4 | 1.38 (1.26-1.51) | <.001 | 9.1 | <.001 |
| Northeast | 0.81 (0.76-0.85) | <.001 | 9.4 | 0.58 (0.52-0.65) | <.001 | 4.0 | <.001 |
| South | 1.51 (1.44-1.58) | <.001 | 15.8 | 1.38 (1.28-1.49) | <.001 | 8.9 | .04 |
| West | 1.00 | 12.2 | 1.00 | 6.4 | |||
| Payer type | |||||||
| Medicare | 1.00 | 14.7 | 1.00 | 7.8 | |||
| Medicaid | 1.02 (0.97-1.09) | .44 | 14.0 | 1.09 (0.98-1.21) | .14 | 8.6 | .34 |
| Charity | 1.19 (0.98-1.44) | .08 | 15.8 | 0.93 (0.62-1.39) | .73 | 7.8 | .28 |
| Managed care | 1.06 (1.01-1.10) | .01 | 15.6 | 0.92 (0.85-1.00) | .04 | 7.8 | .003 |
| Self-pay | 0.90 (0.82-0.98) | .02 | 13.4 | 0.90 (0.77-1.06) | .20 | 7.9 | .96 |
| Workers comp | 1.97 (1.34-2.91) | <.001 | 28.2 | 1.36 (0.57-3.24) | .48 | 12.0 | .45 |
| Government payer† | 0.97 (0.82-1.14) | .70 | 15.1 | 0.76 (0.53-1.10) | .15 | 6.6 | .25 |
| Other or unknown | 0.68 (0.58-0.80) | <.001 | 9.9 | 0.65 (0.48-0.88) | .006 | 5.3 | .76 |
Abbreviations: ACE: angiotensin-converting enzyme; ARB, angiotensin receptor blocker; β-blocker: β-blocker approved for heart failure; CI, confidence interval; OR, odds ratio.
*
All reference groups for concurrent therapies are those individuals not receiving the specific drug.
†
Including the Veterans Health Administration, Tricare, and Indian Health Services.